Authors


Brandi Lewis

Latest:

Closing Reflection: A Journey of Understanding and Resilience

Panelists discuss how emerging treatments, digital health tools, and enhanced care coordination could streamline disease management and improve quality of life while identifying opportunities to strengthen provider communication and access to resources.


Johanna Garibaldi, BSN, RN, EMT-P

Latest:

Johanna Garibaldi On Strengthening Cancer Prevention Tactics With Mobile Screening Clinics

Johanna Garibaldi, BSN, RN, EMT-P, discusses how a mobile clinic improved cancer screening rates among local firefighters.



Katherine Cohen, MSN, FNP-C

Latest:

Evaluating Options for Second-Line HR+, HER2- Breast Cancer Treatment

Katherine Cohen, MSN, FNP-C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment.


Jessica MacIntyre, DNP, MBA, NP-C, APRN, AOCNP

Latest:

Jessica MacIntyre on Improving LLS Referrals For Patients With Hematologic Malignancies

Jessica MacIntyre, DNP, MBA, APRN, NP-C, AOCNP, discusses ways to standardize the process of referring patients to the Leukemia and Lymphoma Society.


Larysa Sanchez, MD

Latest:

Unmet Needs and Future Perspectives on the treatment of R/R MM

Experts provide advice for patients and caregivers with relapsed/refractory multiple myeloma considering talquetamab or another bispecific, while all faculty will discuss unmet needs and future perspectives in the treatment of relapsed/refractory multiple myeloma.


Daniel J. Verina, DNP, RN, MSN, ACNP-BC

Latest:

Verina on Tackling Neurological Toxicities From CAR T-Cell Therapy

Daniel J. Verina, DNP, RN, MSN, ACNP-BC, underscores how nurses can assess neurological toxicities in both the inpatient and outpatient setting.


Laurence Albiges, MD, PhD

Latest:

Nivolumab Combo for RCC Necessitates AE Monitoring, Awareness

According to Laurence Albiges, MD, PhD, treatment of RCC with cabozantinib, nivolumab, and ipilimumab can cause potentially serious toxicities that should be closely monitored.


Jamie Cesanek

Latest:

Forgoing Select Lymph Node Dissection Linked With Superior Outcomes in Early-Stage Breast Cancer

Updates from the ongoing INSEMA trial suggest that patients with early-stage breast cancer maintain superior quality of life by forgoing sentinel lymph node biopsy and axillary lymph node dissection.


Krystle Peterson, PA-C

Latest:

Life After CAR T Therapy: Insights for Patients and Referring Oncologists

This video segment focuses on key elements of patient education and support for long-term CAR-T survivors, strategies to maintain quality of life and manage late effects, differences in supportive care needs between ide-cel and cilta-cel recipients, and approaches to fostering collaboration between academic centers and community practices for optimal long-term care.


Precious Ferguson, MSN, APRN, FNP-BC

Latest:

Supporting the Novice Oncology NP: The Benefits of Preceptorship

Structured preceptorships promote competence, confidence, and job satisfaction in new oncology nurse practitioners.


Jennifer B. Squires, FNP-C, AOCNP

Latest:

Patient-Centered Approaches in EGFR-Mutated NSCLC

Panelists discuss how oral and subcutaneous therapies have improved the quality of life for patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), with Squires sharing patient benefits from newer administration routes, and Dr Scott highlighting promising developments in EGFR-mutated NSCLC treatments, while exploring the evolving role of patient empowerment, self-management, and the multidisciplinary care team in supporting patients through home-based care and active participation in their treatment journey.


Lucia Fanjul, LMSW

Latest:

Immediate Interventions to Support The Newly Bereaved

When engaging with a family member of a patient who has died, nurses should consider using immediate interventions aimed at supporting the loved ones who are in shock and in pain following their loss.


Jennifer Cargile, MEd, CCC-SLP

Latest:

Jennifer Cargile on Managing Cancer-Related Cognitive Impairment

Jennifer Cargile, MEd, CCC-SLP, shares some examples of how she helped patients continue their daily activities while they experienced symptoms of cancer-related cognitive impairment.


Chris Ryan

Latest:

Subcutaneous Nivolumab Maintains Comparable Efficacy, Safety to IV in ccRCC

The subcutaneous formulation of nivolumab showed comparable efficacy and safety to the IV formulation in advanced clear cell renal cell carcinoma.


Jamie Carroll, APRN, CNP, MSN

Latest:

Liquid Biopsies Are More Feasible, Appropriate for ESR1+ Breast Cancer

Using liquid biopsies to test for ESR1 mutations in breast cancer is more feasible for patients and has quicker turnaround times.


Yale Cancer Center

Latest:

Oncology Therapy at the End of Life: Have We Missed the Mark?

"Over the last decade, the landscape of systemic anti-cancer therapy has changed dramatically following the approvals of multiple new targeted therapies," - Kerin Adelson, MD.


Kristine Gibbons, RN, OCN

Latest:

Oncology Drug Crash Course: Elacestrant (Orserdu)

Kristine Gibbons, RN, OCN, who is a Nurse Trainer at Florida Cancer Specialists & Research Institute, provides an in-depth look at elacestrant in a downloadable fact sheet.


Charina Toste, DNP, APRN-C, AOCNP, MSN, BSN, RN

Latest:

Charina Toste Discusses the Educational Obstacles Patients With MPNs Face

According to Charina Toste, DNP, APRN-C, AOCNP, MSN, BSN, RN, patients with newly diagnosed myeloproliferative neoplasms may be unaware of the questions they should be asking their providers.


Erin Burns, PhD

Latest:

Advanced Practice Providers May Hold the Key to Improving Community Clinical Trial Involvement

Seventy-three percent of advanced practice providers reported that they are interested in becoming more involved with clinical trials.


Hussein A. Tawbi, MD, PhD

Latest:

Expert Talks Significance of Relatlimab/Nivolumab Approval for Metastatic Melanoma

Hussein A. Tawbi, MD, PhD, principal investigator of the phase 2/3 RELATIVITY-046 trial, highlights the importance of relatlimab/nivolumab’s recent FDA approval in melanoma.


Marni Jameson Carey

Latest:

Is a Health Care Price Transparency Revolution at Hand?

The Transparency in Coverage Final Rule requires health care payers to unveil all previously secret negotiated prices with in-network providers.



David Zhen, MD

Latest:

Bridging Communication Gaps: Comprehensive Care for Upper GI Cancer Treatment

Experts discuss how to facilitate open communication among the patient, caregivers, and the multidisciplinary team to ensure comprehensive care and alignment on treatment goals.


Areyl Goff, APNP

Latest:

Referral Process With Bispecifics: Challenges and Support

Dr Mohan engages with Dr Mann, Nurse Brigle, Nurse Distaso, and Dr Nadeem to explore challenges in the referral process for bispecific therapy, including local health care barriers, and strategies for ensuring consistent patient education and support when care is shared between community and academic centers.


Meera Mohan, MD

Latest:

Referral Process With Bispecifics: Challenges and Support

Dr Mohan engages with Dr Mann, Nurse Brigle, Nurse Distaso, and Dr Nadeem to explore challenges in the referral process for bispecific therapy, including local health care barriers, and strategies for ensuring consistent patient education and support when care is shared between community and academic centers.


Matt Iwaniec, PsyD

Latest:

Integrated Behavioral Health Vs Standard Practice: What’s The Difference?

A licensed clinical health psychologist with Allegheny Health Network discusses fully integrated behavioral health programs and how their design alleviates potential barriers to care that patients may experience.


Sabrina Serani

Latest:

FDA Approves Ensartinib To Treat Frontline ALK+ NSCLC

Ensartinib has received FDA approval for the first-line treatment of ALK-positive locally advanced or metastatic non–small cell lung cancer.


Claudia Calderon, NP

Latest:

Bridging Communication Gaps: Comprehensive Care for Upper GI Cancer Treatment

Experts discuss how to facilitate open communication among the patient, caregivers, and the multidisciplinary team to ensure comprehensive care and alignment on treatment goals.


Rina Lokaj

Latest:

Adding Nivolumab to Chemo Increases OS, PFS in Previously Untreated Advanced GI Cancers

Overall survival and progression-free survival improves with nivolumab plus chemotherapy compared with chemotherapy alone in the overall population and in patients with a PD-L1 CPS of 5 or greater.